

1 **Development of a bedside score to predict dengue severity.**

2 **Running title:** Severe Dengue: operational predictive model

3 Ingrid Marois, MD^{1¶}, Carole Forfait, PhD^{2¶}, Catherine Inizan, PhD^{3¶}, Elise Klement-Frutos, MD^{1¶*},
4 Anabelle Valiame, MD², Daina Aubert, MD², Ann-Claire Gourinat, PharmD⁴, Sylvie Laumond, MD²,
5 Emilie Barsac, MSc⁴, Jean-Paul Grangeon, MD², Cécile Cazorla, MD¹, Audrey Merlet, MD¹, Arnaud
6 Tarantola, MD, PhD⁵, Myrielle Dupont-Rouzeyrol, PhD³, Elodie Descloux, MD, PhD^{1¶†}.

7
8 ¹ Internal medicine and infectious diseases department, Territorial Hospital Center (CHT), Dumbea, New
9 Caledonia

10 ² Health Authorities (DASS), Noumea, New Caledonia

11 ³ Institut Pasteur in New Caledonia, URE Dengue and Arboviruses, Noumea, New Caledonia

12 ⁴ Microbiology laboratory, Territorial Hospital Center (CHT), Dumbea, New Caledonia

13 ⁵ Institut Pasteur in New Caledonia, URE Epidemiology, Noumea, New Caledonia

14

15 [¶] These authors contributed equally to this work.

16 † In memoriam our dear colleague Dr Elodie Descloux who was deeply involved in arboviruses research
17 in New Caledonia.

18

19 ***Corresponding author:**

20 Dr Elise Klément-Frutos

21 Hôpitaux Universitaires Pitie Salpetriere-Charles Foix

22 47-83 Bd de l'Hôpital, 75651 Paris cedex 13

23 (+33) 1 42 16 00 00

24 elisemarie.klement@aphp.fr

25

26 **Abstract**

27 **Background**

28 In 2017, New Caledonia experienced an outbreak of severe dengue causing high hospital burden (4,379
29 cases, 416 hospital admissions, 15 deaths). We decided to build a local operational model predictive of
30 dengue severity, which was needed to ease the healthcare circuit.

31 **Methods**

32 We retrospectively analyzed clinical and biological parameters associated with severe dengue in the
33 cohort of patients hospitalized at the Territorial Hospital between January and July 2017 with confirmed
34 dengue, in order to elaborate a comprehensive patient's score. Patients were compared in univariate and
35 multivariate analyses. Predictive models for severity were built using a descending step-wise method.

36 **Results**

37 Out of 383 included patients, 130 (34%) developed severe dengue and 13 (3.4%) died. Major risk factors
38 identified in univariate analysis were: age, comorbidities, presence of at least one alert sign, platelets
39 count $<30 \times 10^9/L$, prothrombin time $<60\%$, AST and/or ALT $>10N$, and previous dengue infection.

40 Severity was not influenced by the infecting dengue serotype nor by previous Zika infection.

41 Two models to predict dengue severity were built according to sex. Best models for females and males
42 had respectively a median Area Under the Curve = 0.80 and 0.88, a sensitivity = 84.5% and 84.5%, a
43 specificity = 78.6% and 95.5%, a positive predictive value = 63.3% and 92.9%, a negative predictive
44 value = 92.8% and 91.3%. Models were secondarily validated on 130 patients hospitalized for dengue in
45 2018.

46 **Conclusion**

47 We built robust and efficient models to calculate a bedside score able to predict dengue severity in our
48 setting. We propose the spreadsheet for dengue severity score calculations to health practitioners facing
49 dengue outbreaks of enhanced severity in order to improve patients' medical management and
50 hospitalization flow.

51

52 Keywords: Dengue, arboviruses, severity score, operational tool, hospital triage, Pacific

53

54 **Background**

55 Dengue fever is the most prevalent human arbovirolosis and a major public health issue in tropical and
56 sub-tropical countries with epidemic outbreaks (1, 2). Dengue viruses are subdivided in 4 serotypes
57 (DENV-1 to -4). There is a lack of specific treatments, vector control measures regularly fail to prevent
58 epidemics and safe preventive dengue vaccines are not widely available (3-5). While new prevention
59 methods are being developed, clinical management strategies are of prime importance.

60 Dengue has a wide spectrum of clinical presentations usually starting by an abrupt onset of fever, malaise,
61 skin rash, headache, anorexia/vomiting, diarrhea, and abdominal pain, often with unpredictable clinical
62 evolution. Clinical outcome can vary from a self-limiting non-severe condition to a potentially lethal
63 disease subsequent to a vascular permeability resulting in leakage of fluids into serosal cavities and
64 shock, hemorrhages, and/or organ failures (4). Warning signs of severe dengue include persisting
65 vomiting, abdominal pain, lethargy/anxiety, mucosal bleeding, liquid accumulation, hepatomegaly, and
66 rapid hematocrit increase concurrent with a platelet count drop (4).

67 In New Caledonia (NC), a French South Pacific Island Territory of 270,000 inhabitants, dengue is a
68 closely monitored notifiable disease, enabling the collection of reliable documentation of dengue cases.
69 Dengue fever outbreaks frequency is increasing in NC (**Fig 1**), and is associated to the emergent co-
70 circulation of several DENV serotypes and other arboviruses, i.e. chikungunya and Zika viruses (6-8).
71 An uninterrupted circulation of DENV-1 has been documented in NC between 2007 and 2018.

72 During the 2017 dengue outbreak, three serotypes have co-circulated (DENV-1, DENV-2, DENV-3) for
73 the first time. 4,379 dengue cases were declared among which 2,372 (54%) were biologically confirmed
74 by RT-qPCR (6). Fifteen patients died (lethality rate= 0.3%). The hospitalization rate was exceptionally
75 high (11.5% versus 3.5% during the 2012-2013 outbreak, 2.1% during the 2008-2009 outbreak, and 4.5%
76 during the 2003 outbreak).

77 Identifying risk factors for severe dengue is of prime importance to improve patients' medical care and
78 better manage in-hospital patient flow. Such risk factors may differ depending on the region of the world
79 considered, in link with populations' genetics and way of living. To our knowledge, risk factors for
80 severe dengue have been mostly explored in countries where dengue is endemic and have never been
81 explored in the Pacific region, where dengue has an epidemic mode of circulation. Assessing the
82 reliability of identified risk factor for severe dengue in epidemiological contexts where dengue has an
83 epidemic mode of circulation is important to relieve the health care system upon outbreaks. Furthermore,

84 the expansion of dengue in more temperate countries will certainly lead the hospitals to be overwhelmed,
85 and operational tools developed in epidemic countries would help better manage in-hospital patient flow.
86 In 2014-2015, the Pacific region and South America experienced a Zika pandemic. This pandemic
87 occurred in countries where dengue circulates actively, it is therefore crucial to determine whether a
88 previous Zika infection represents a risk factor for severe dengue.
89 The purposes of this study were to investigate clinical and biological parameters associated with severe
90 dengue and elaborate an operational model to score patients' risk to develop severe dengue in the NC
91 medical facilities setting.

92 **Methods**

93 **Study population**

94 A total of 416 patients were admitted to the Territorial Hospital of New Caledonia between January 1st
95 2017 and July 31st 2017 with a diagnosis of dengue fever. Among them, 385 were biologically confirmed
96 using RT-qPCR (9), of which 383 were enrolled in this study (**Supplementary Fig1**).

97 **Data collection**

98 Patients' clinical and biological characteristics were retrieved from hospital medical records (DxCare-
99 Medasys), dengue notification sheets and completed by a telephone interview using a standardized
100 questionnaire. Collected data included patients' gender, age, ethnicity, medical history, treatments,
101 substance abuse (tobacco, alcohol >3 units/day, cannabis, kava), clinical and biological parameters,
102 presence of warning and severe signs, infecting dengue serotype and previous dengue and Zika infection.
103 Dengue serotyping by RT-qPCR and IgG serology for dengue (PanBio®) and Zika (Euroimmun®) were
104 performed.

105 **Patients Classification**

106 Disease severity was assessed according to the WHO 2009 criteria (4). Patients were classified as severe
107 when they displayed at least one of the following criteria: severe plasma leakage (shock, liquid
108 accumulation visualized by sonogram or x-ray) with respiratory distress; severe hemorrhage; and/or
109 severe organ failure (kidney, central nervous system, liver, heart). Thrombocytopenia with platelet count
110 under $10 \times 10^9/L$ (reference range $150-400 \times 10^9/L$) associated to minor bleeding was used as an additional
111 severity criterion. Acute renal failure was defined as a Glomerular Filtration Rate by the MDRD Equation
112 $<60 \text{ mL/min/1.73m}^2$ or, for patients with previous chronic renal failure, a 2-fold increase from their
113 baseline creatinine level. Severe hepatitis was defined by a transaminase (AST or ALT) level above
114 1000IU/L.

115 **Statistical Analysis and Predictive Models construction**

116 For each quantitative variable, minimum, maximum, mean and median were calculated. Quantitative
117 variables age and biological parameters were categorized into qualitative variables. Non-severe patients

118 were compared to severe patients. In the univariate analysis, Odds Ratio (OR) and 95% confidence
119 interval were calculated. Test of independence p -values were estimated using Fisher's exact test.
120 Differences were considered significant if $p < 0.05$. Parameters for which Fisher test $p \leq 0.2$ were used to
121 perform the multivariate analysis. Odds ratio were adjusted for each variable category with the value of
122 the other variables being fixed. A predictive model for severe dengue was built using multiple logistic
123 regression and a descending stepwise analysis. Statistics were performed using R software (version 3.5.1
124 (2018-07-02)).

125 **Predictive models validation**

126 A k-fold cross-validation procedure ($k=10$) was used. The subsample k was retained as validation data
127 and the remaining $k-1$ subsamples were used as training data. The cross-validation process was repeated
128 k times, each of the k subsamples used exactly once as the validation data. Model performance was
129 measured using the following indicators: sensitivity, specificity, positive predictive value, negative
130 predictive value, Yule index (10), Youden index (sensitivity + specificity - 1) [(11) and the Area Under
131 Curve (AUC) of the Receiving Operating Characteristic (ROC) curve. Using the variable coefficients
132 determined in the logistic regression, patients' score was expressed as p (probability to develop a severe
133 dengue). The decision-making threshold was defined using the ROC curve as the best combination of
134 sensitivity and specificity.

135 **Ethics Statement**

136 Ethical approval was granted by the Consultative Ethics Committee of NC, and by the internal ethical
137 review board of the Territorial Hospital. Dengue fever is a compulsory declarative disease in NC. Oral
138 informed consent was obtained from all participating patients or their relatives retrospectively when
139 consulted by telephone.

140

141 **Results**

142 **Characteristics of the studied population**

143 The characteristics of the 383 PCR-confirmed dengue patients included in this study are presented in
144 **Table 1**. Patients were hospitalized on average on the 5th day after symptom onset (median = 4, IQR =
145 3), for a median duration of 4 days (IQR = 3). They were 174 men and 209 women (Sex-ratio=0.83) with
146 an age ranging from birth to 96 years old (IQR = 34, median 32 years). Symptoms and biological
147 parameters available at hospital admission are summarized in **Table 2**. DENV-1 was the major serotype
148 (80.6%), followed by DENV-2 (15.9%) and DENV-3 (3.6%). According to the WHO 2009
149 classification, 299/383 patients (78%) displayed at least one warning sign. Overall, 130 patients (34%)
150 developed severe dengue.

151 While 121 patients (40%) with at least one warning sign developed severe dengue, only nine patients
152 (10.7%) without warning signs did so (**Fig 2**). The Odds ratio (OR) for patients presenting at least one
153 warning sign is 5.6 [2.17; 13.3], with a corresponding Relative Risk of 3.8 [2.0; 7.1]. Hepatitis was the
154 most frequent severity criterion accounting for 41.5% of severe cases. Twenty-two patients (5.7%)
155 developed major hemorrhage, 47 (12.3%) had deep thrombocytopenia $<10 \times 10^9/L$ with minor bleeding,
156 and 26 (6.8%) developed a shock, corresponding to 16.9%, 36.2% and 20% of severe cases, respectively
157 (**Fig 3**). A total of 182 (47.5%) patients presented comorbidities. The most frequent comorbidity was
158 obesity (24.8%), accounting for 33.1% of severe cases (**Table 1**). Thirteen patients died (lethality rate =
159 3.4%): ten during hospitalization and three after discharge. In-hospital deaths involved 7/10 patients
160 younger than 55 years old without notable medical history. Previous dengue infection was recorded in
161 7/8 patients who died within a week; all three circulating serotypes were involved, including one case of
162 coinfection.

163 **Factors associated with severe dengue in univariate analysis**

164 Factors highly associated with severe dengue in univariate analysis included age]20-30] years and > 60
165 years (OR 2.22 and 3.26), comorbidities (hypertension OR 2.63, obesity OR 1.91, dyslipidaemia OR
166 2.22 and more than two comorbidities OR 1.98), previous dengue infection (OR 4.7), use of platelet
167 aggregation inhibitors (OR 2.1), presence of at least one alert sign (OR 5.6) and prothrombin time < 60%
168 (OR 7.2) (**Table 1**).

169 **Multivariate analysis and construction of the predictive models**

170 Variables significantly associated with dengue severity in univariate analysis with $p \leq 0.2$ and available at
171 hospital admission were taken into account in the multivariate analysis. These variables were:
172 comorbidities (hypertension, myocardiopathy, dyslipidemia, obesity), excessive tobacco and alcohol
173 consumption, anticoagulant or use of platelet aggregation inhibitors, mucosal bleeding, hematuria and/or
174 presence of blood in stools, skin rash, clinical liquid accumulation, abdominal pain, simultaneous
175 hematocrit increase and platelet count drop, platelets $< 30 \times 10^9/L$, ALT and/or AST $> 10N$. Raw analysis
176 of the dataset showed that certain age groups in females were more at risk to develop severe dengue,
177 while no difference was observed between age groups in men. This suggested the existence of an
178 interaction between age and sex. This interaction was confirmed using a bivariate analysis taking age
179 and sex as variables. Multivariate analysis further confirmed this interaction between age and sex: women
180 between 20 and 30 years and men over 60 years were more at risk for severe dengue (OR 4.02 and 3.17,
181 respectively). An analysis for each modality of the variable sex was thus performed and two different
182 predictive models were built according to sex.

183 Descending stepwise analysis identified the best explanatory variables for progression towards severe
184 dengue (**Table 3**). In the model for females, these variables were: age class, hypertension, skin rash,
185 mucosal bleeding, platelets count $< 30 \times 10^9/L$ and ALT $> 10N$. In the model for males, these variables
186 were: age class, excessive alcohol consumption, mucosal bleeding, platelets count $< 30 \times 10^9/L$ and ALT
187 $> 10N$. The predictive models provide a score. Score threshold is derived from the ROC curve as the
188 threshold optimal value for which sensitivity and specificity are the highest for the whole dataset. A score
189 ≥ 0.36 for females and ≥ 0.34 for males indicates a high probability to develop severe dengue. The Excel
190 spreadsheet enabling the calculation of this risk score is presented in **Supplementary Fig2**. Examples of
191 models' usage are presented in **Supplementary Fig3**.

192 **Performance of the models**

193 A k-fold cross-validation procedure ($k=10$) showed that both models for females and males were robust
194 and efficient (**Fig 4**), yielding a median AUC of 0.80 (Interquartile Range IQR = 0.08, range [0.638;
195 0.952]) and 0.88 (IQR=0.13, range [0.701; 1.00]), respectively and a high median Negative Predictive
196 Value (92.8 and 91.3%, respectively). Models were challenged on a cohort of 130 patients (66 females,
197 64 males) hospitalized for dengue in NC in 2018. Contingency tables depicting the number of severe

198 dengue cases among the 2018 dataset and the number of severe dengue retrieved from models predictions
199 are shown in **Supplementary Fig4**. Models for females and males yielded a sensitivity of 73 and 84%,
200 a specificity of 88 and 71%, a Positive Predictive Value of 65 and 55%, a Negative Predictive Value of
201 92 and 91%, a Youden index of 0.62 and 0.55 and a Yule Q index of 0.91 and 0.62, respectively.

202 Discussion

203 The 2017 dengue outbreak in New Caledonia was characterized by a high hospitalization rate leading to
204 an overwhelming of emergency rooms and hospitalization units. Clinicians and epidemiologists
205 expressed the necessity to develop a comprehensive operational tool in order to improve medical care
206 and in-patients flow in local hospitals. Based on a detailed analysis of 383 hospitalized patients, we
207 identified important demographical, clinical and biological parameters associated with severe dengue.
208 Parameters easily available in routine practice were used to score patients' risk of developing severe
209 dengue.

210 Most of the risk factors we identified in univariate analysis have been described in other studies, i.e. age
211 (12, 13), comorbidities such as hypertension (14) or diabetes (12, 14, 15), persistent vomiting (13, 16),
212 increase in hematocrit (12, 16). Therefore, we confirm that the WHO 2009 criteria to evaluate the severity
213 of dengue infection are applicable in NC. A platelet count $<30 \times 10^9/L$ was also strongly associated with
214 severe dengue in our study (OR 4.5) like in other studies (12, 16, 17). However, no consensus on severe
215 thrombocytopenia definition was obtained in a recent working group of dengue researchers and public
216 health specialists to develop standardized endpoints, and they remained divided on whether a rapid
217 decreasing trend or a specific platelet count should be case-defining (18). Factors not associated with
218 severity in NC are sex, ethnicity and substance abuse. In our study, the detected serotype responsible for
219 the acute infection is not linked to the severity of the disease, unlike previous findings (19).

220 We report a 4.7 fold increased risk of severe dengue in patients who had a serologically documented
221 history of previous dengue infection, in accordance with the Antibody-Dependent Enhancement (ADE)
222 theory stating that secondary dengue infections are usually more severe (20). However, as dengue
223 serology is usually not available at hospital admission, the presence of dengue IgG antibodies was not
224 included in our multivariate analysis. For the first time to our knowledge, we have investigated the
225 influence of a previous Zika infection on dengue outcome, and we found no association with dengue
226 severity. As DENV and ZIKV serological tests display partial cross-reactivity (21), the impact of
227 previous DENV and ZIKV infection on dengue severity should be confirmed by seroneutralization tests.
228 We were able to build two robust and efficient logistic regression models to evaluate patients' risk of
229 developing severe dengue in men and women. These models enable the calculation of a risk score based
230 on simple parameters and may represent easy-to-use operational tools to help clinicians in hospitalization
231 decision and improve in-hospital patient flux (**Supplementary Fig 2&3**). Different predictive models

232 have been proposed in previous studies, based on multivariate logistic regression (22-24) or on
233 classification and regression trees (25, 26). Parameters used in these models were mainly age,
234 leukocytosis and platelet count. Interestingly, Nguyen et al. developed a prognostic model taking into
235 account vomiting, platelet count ($< 10 \times 10^9/L$), AST level (2-fold increase) and NS1 rapid test status (24).
236 The model they propose yielded a very good discriminative ability (AUC 0.95), which is close to the
237 AUC of 0.80 and 0.88 yielded by our models for females and males, respectively. However, a major
238 caveat to their study is the absence of model cross-validation.

239 The bedside scoring tool we propose is very simple and easy to use, results ranging from 0 (minimal risk
240 of severe dengue) to 1 (maximal risk). When a patient refers to the hospital with probable or confirmed
241 dengue fever and has no other classical criteria of hospitalization, we calculate his severity score. If it is
242 ≤ 0.34 for a man and ≤ 0.36 for a woman, we invite the patient to go back home and to be reassessed by a
243 physician at day 4-6 post-symptoms' onset. If the score is greater, we propose an admission for IV fluid
244 treatment and bio-clinical monitoring. If the score is > 0.6 the patient should be closely monitored and if
245 it is > 0.8 he might require intensive care. We also systematically recommend ICU admission when
246 platelet count is $< 10 \times 10^9/L$ or transaminases > 2000 IU/L.

247 Although based on a well-documented and validated database, biological data were heterogeneous as
248 collected at different time points after symptoms' onset, but this limit is inherent to retrospective studies.
249 As our studied population was composed of relatively old patients (which is a characteristic of dengue
250 epidemiology in NC), hospitalized in a single hospital (albeit the largest in NC), our models may not be
251 valid to predict patients' risk to develop severe dengue in other populations. However, our models were
252 prospectively validated on 130 patients during 2018 DENV-2 outbreak in NC, yielding a high Negative
253 Predictive Value of 92 and 91% for females and males respectively. Our models could thus be relevant
254 for dengue severity prediction regardless of the incriminated serotype.

255 **Conclusions**

256 We developed a bedside score to predict dengue severity. We propose this bedside score to be deployed
257 and tested in other countries with similar dengue epidemiology, in order to optimize patients' triage, in-
258 hospital patients flux, and improve personalized medical care, thus benefiting both health practitioners
259 and populations facing dengue outbreaks of enhanced severity.

Abbreviations

ADE: Antibody-Dependent Enhancement

ALT: Alanine Aminotransferase

AST: Aspartate Aminotransferase

AUC: Area Under the Curve

DENV: dengue virus

ICU: Intensive Care Unit

IgG: type G Immunoglobulin

IQR: Interquartile Range

IU/L : International Units/L

NC : New Caledonia

NS1: Non-Structural protein 1

OR: Odds Ratio

ROC curve: Receiving Operating Characteristic curve

RT-qPCR : Reverse Transcription-quantitative Polymerase Chain Reaction

WHO: World Health Organization

ZIKV: Zika virus

Declarations

Ethics approval and consent to participate

Ethical approval was granted by the Consultative Ethics Committee of NC, and by the internal ethical review board of the Territorial Hospital. Dengue fever is a compulsory declarative disease in NC. Oral informed consent to participate was obtained from all participating patients or their relatives retrospectively when consulted by telephone.

Consent to publish

Not applicable.

Availability of data and materials

All data generated or analysed during this study are included in this published article

Competing interests

The authors declare no conflict of interest.

Funding

This work was supported by the government of New Caledonia. The funder provided financial support to the study but did not participate in the design of the study, data collection, analysis, and interpretation or writing of the manuscript.

Authors' Contributions

ED, AV and CF conceived the study, IM, EK-F, CC, AM, ED recruited the patients. A-CG, EB performed the biological analyses. IM, CI, CF, AT, ED analyzed the data, CF performed the statistical analyses, AV, DA, SL, J-PG provided access to patients' data. CI, AT, MD-R, IM, ED and EK-F wrote the manuscript, IM, CF, CI, EK-F and ED contributed equally to this work, all authors carefully revised the manuscript.

Acknowledgements

We thank Sébastien Mabon, Sophie Lafleur, Pascal André, and Mathieu Serié from CHT Noumea for their help during this study, Antoine Biron, Marie-Amélie Goujart, Nathalie Amedeo, Erwan Choblet,

Gauthier Delvallez from CHT Laboratory. We thank Ludovic Floury, Viktoria Taofifenua, Anne Pfannstiel from DASS-NC, Morgan Mangeas and Magali Teurali (IRD) for their help in statistics.

References

1. Guzman MG, Gubler DJ, Izquierdo A, et al. Dengue infection. *Nature reviews Disease primers*. 2016;2:16055. Epub 2016/08/19.
2. Bhatt S, Gething PW, Brady OJ, et al. The global distribution and burden of dengue. *Nature*. 2013;496(7446):504-7. Epub 2013/04/09.
3. Sridhar S, Luedtke A, Langevin E, et al. Effect of Dengue Serostatus on Dengue Vaccine Safety and Efficacy. *The New England journal of medicine*. 2018;379(4):327-40. Epub 2018/06/14.
4. WHO. *Dengue: Guidelines for Diagnosis, Treatment, Prevention and Control: New Edition*. 2009.
5. WHO. Dengue vaccine: WHO position paper – September 2018 – Note de synthèse de l’OMS sur le vaccin contre la dengue– septembre 2018. *Weekly Epidemiological Record = Relevé épidémiologique hebdomadaire*. 2018;93 (36), 457 - 76.
6. DASS-NC. Documents, rapport, études - La situation sanitaire de la Nouvelle-Calédonie.
7. Dupont-Rouzeyrol M, Aubry M, O'Connor O, et al. Epidemiological and molecular features of dengue virus type-1 in New Caledonia, South Pacific, 2001-2013. *Virology journal*. 2014;11:61. Epub 2014/04/02.
8. Inizan C, Tarantola A, O'Connor O, et al. Dengue in New Caledonia: Knowledge and Gaps. *Tropical medicine and infectious disease*. 2019;4(2). Epub 2019/06/23.
9. CDC. Triplex real-time RT-PCR assay instruction for use. 2017 [12.20.2018]; Available from: <https://www.cdc.gov/zika/pdfs/trioplex-real-time-rt-pcr-assay-instructions-for-use.pdf>.
10. Yule GaP, K VII. On the association of attributes in statistics: with illustrations from the material of the childhood society. *Philosophical Transactions of the Royal Society of London Series A, Containing Papers of a Mathematical or Physical Character*. 1900;194(252-261):257-319.
11. Youden W. Index for rating diagnostic tests. *Cancer*. 1950 Jan;3(1):32-5.
12. Pang J, Hsu JP, Yeo TW, et al. Diabetes, cardiac disorders and asthma as risk factors for severe organ involvement among adult dengue patients: A matched case-control study. *Scientific reports*. 2017;7:39872. Epub 2017/01/04.
13. Amancio FF, Heringer TP, de Oliveira Cda C, et al. Clinical Profiles and Factors Associated with Death in Adults with Dengue Admitted to Intensive Care Units, Minas Gerais, Brazil. *PloS one*. 2015;10(6):e0129046. Epub 2015/06/20.
14. Pang J, Salim A, Lee VJ, et al. Diabetes with hypertension as risk factors for adult dengue hemorrhagic fever in a predominantly dengue serotype 2 epidemic: a case control study. *PLoS neglected tropical diseases*. 2012;6(5):e1641. Epub 2012/05/09.
15. Figueiredo MA, Rodrigues LC, Barreto ML, et al. Allergies and diabetes as risk factors for dengue hemorrhagic fever: results of a case control study. *PLoS neglected tropical diseases*. 2010;4(6):e699. Epub 2010/06/10.
16. Leo YS, Thein TL, Fisher DA, et al. Confirmed adult dengue deaths in Singapore: 5-year multi-center retrospective study. *BMC infectious diseases*. 2011;11:123. Epub 2011/05/17.
17. Bouldouyre MA, Baumann F, Berlioz-Arthaud A, et al. Factors of severity at admission during an epidemic of dengue 1 in New Caledonia (South Pacific) in 2003. *Scandinavian journal of infectious diseases*. 2006;38(8):675-81. Epub 2006/07/22.
18. Tomashek KM, Wills B, See Lum LC, et al. Development of standard clinical endpoints for use in dengue interventional trials. *PLoS neglected tropical diseases*. 2018;12(10):e0006497. Epub 2018/10/05.
19. Vicente CR, Herbinger KH, Fröschl G, et al. Serotype influences on dengue severity: a cross-sectional study on 485 confirmed dengue cases in Vitória, Brazil. *BMC infectious diseases*. 2016;16:320. Epub 2016/07/10.
20. Guzman MG, Alvarez M, Halstead SB. Secondary infection as a risk factor for dengue hemorrhagic fever/dengue shock syndrome: an historical perspective and role of antibody-dependent enhancement of infection. *Archives of virology*. 2013;158(7):1445-59. Epub 2013/03/09.
21. Zaidi MB, Cedillo-Barron L, Gonzalez YAME, et al. Serological tests reveal significant cross-reactive human antibody responses to Zika and Dengue viruses in the Mexican population. *Acta tropica*. 2019:105201. Epub 2019/09/29.
22. Carrasco LR, Leo YS, Cook AR, et al. Predictive tools for severe dengue conforming to World Health Organization 2009 criteria. *PLoS neglected tropical diseases*. 2014;8(7):e2972. Epub 2014/07/11.

23. Lee IK, Liu JW, Chen YH, et al. Development of a Simple Clinical Risk Score for Early Prediction of Severe Dengue in Adult Patients. *PloS one*. 2016;11(5):e0154772. Epub 2016/05/04.
24. Nguyen MT, Ho TN, Nguyen VV, et al. An Evidence-Based Algorithm for Early Prognosis of Severe Dengue in the Outpatient Setting. *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America*. 2017;64(5):656-63. Epub 2016/12/31.
25. Potts JA, Gibbons RV, Rothman AL, et al. Prediction of dengue disease severity among pediatric Thai patients using early clinical laboratory indicators. *PLoS neglected tropical diseases*. 2010;4(8):e769. Epub 2010/08/07.
26. Phakhounthong K, Chaovalit P, Jittamala P, et al. Predicting the severity of dengue fever in children on admission based on clinical features and laboratory indicators: application of classification tree analysis. *BMC pediatrics*. 2018;18(1):109. Epub 2018/03/15.

Tables

Table 1. Characteristics of 383 hospitalized patients during the 2017 dengue outbreak in New Caledonia and results of the univariate analysis

Characteristics	Number (%)	Non severe cases (%) n = 253	Severe cases (%) n = 130	Odds ratio [CI 95%] p value
Sex				
Men	174 (45.4%)	109 (43.1%)	65 (50%)	1.32 [0.86-2.02] p=0.23
Women	209 (54.6%)	144 (56.9%)	65 (50%)	Reference
Age class				
< 10 years old	48 (12.4%)	39 (15.4%)	9 (6.9%)	0.77 [0.28-2.06] p=0.63
[10-20]	69 (18.0%)	50 (19.8%)	19 (14.6%)	1.26 [0.55-2.98] p=0.68
[20-30]	72 (18.8%)	43 (17%)	29 (22.3%)	2.22 [1.01-5.11] p=0.05
[30-40]	52 (13.6%)	40 (15.8%)	12 (9.2%)	Reference
[40-50]	42 (11.0%)	26 (10.3%)	16 (12.3%)	2.03 [0.83-5.11] p=0.17
[50-60]	39 (10.2%)	24 (9.5%)	15 (11.5%)	2.06 [0.82-5.26] p=0.16
[60-70]	24 (6.3%)	12 (4.7%)	12 (9.2%)	3.26 [1.16-9.44] p=0.03
> 70	37 (9.7%)	19 (7.5%)	18 (13.8%)	3.10 [1.25-7.97] p=0.02
Self-declared ethnicity				
Melanesian	141 (36.7%)	92(36.4%)	49 (37.7%)	1.30 [0.73-2.34] p=0.37
European	86 (22.5%)	61 (24.1%)	25 (19.2%)	Reference
Polynesian	68 (17.8%)	43 (17%)	25 (19.2%)	1.40 [0.71-2.81] p=0.39
Métis /Other	63 (16.4%)	44(17.3%)	19(14.6%)	1.05 [0.51-2.15] p=1
Not specified	25 (5.1%)	12 (9.2%)	5 (3.8%)	2.23[0.88-5.66] p=0.09
Risky behavior				

Tobacco	105 (27.4%)	62 (24.5%)	43 (33.1%)	1.52 [0.95-2.42] $p=0.09$
Cannabis	19 (4.9%)	12 (4.7%)	7 (5.4%)	1.15 [0.41- 2.97] $p=0.81$
Kava ^a	15 (3.9%)	10 (3.9%)	5 (3.8%)	0.98 [0.29-2.89] $p=1$
Alcohol (>3 units/day)	9 (2.3%)	4 (1.6%)	5 (3.8%)	2.46 [0.62-10.56] $p=0.17$
Comorbidities				
Obesity	95 (24.8%)	52 (20.6%)	43 (33.1%)	1.91 [1.18-3.07] $p=0.08$
Diabetes	34 (8.8%)	20 (7.9%)	14 (10.8%)	1.41 [0.67-2.89] $p=0.35$
Dyslipidemia	27 (7.0%)	13 (5.1%)	14 (10.8%)	2.22 [1.0-4.97] $p=0.06$
Hypertension	66 (17.2%)	31 (12.3%)	35 (26.9%)	2.63 [1.53-4.54] $p<0.01$
Heart disease	21 (5.5%)	11 (4.3%)	10 (7.7%)	1,83 [0.74-4.51] $p=0.23$
Lung diseases	31 (8.1%)	24 (9.5%)	7 (5.4%)	0.55 [0.21-1.26] $p=0.23$
Renal failure	9 (2.3%)	4 (1.6%)	5 (3.8%)	2.46 [0.62-10,56] $p=0.17$
Immunodepression	7 (1.8%)	5 (2%)	2 (1.5%)	0.81 [0.10- 3.99] $p=1$
Cancer	14 (3.7%)	8 (3.2%)	6 (4.6%)	1.49 [0.47-4.46] $p=0.57$
Risk of bleeding ^b	9 (2.3%)	6 (2.4%)	3 (2.3%)	1.0 [0.20-3.97] $p=1$
Number of clinical problems				
No medical history	201 (52.5%)	142 (56.1%)	59 (45.4%)	Reference
1	87 (22.7%)	59 (23.3%)	28 (21.5%)	1.04 [0.58-1.80] $p=1$
2 or more	95 (24.8%)	52 (20.6%)	43 (33.1%)	2.12 [1.29-3.49] $p<0.01$
History of arbovirus infection				
Presence of dengue IgG	132 (34.5%)	68 (26.9%)	64 (49.2%)	2.93 [1.83-4.75] $p<0.001$
Presence of Zika IgG	42 (11.0%)	25 (9.9%)	17 (13.1%)	1.30 [0.66-2.53] $p=0.49$
Treatment				
Paracetamol	300 (78.3%)	203 (80.2%)	97 (74.6%)	0.72 [0.44-1.20] $p=0.24$

Corticosteroids	2 (0.5%)	0	2 (1.5%)	-
NSAI	6 (1.6%)	4 (1.6%)	2 (1.5%)	1.00 [0.12- 5.56] $p=1$
Anticoagulants	9 (2.3%)	3 (1.2%)	6 (4.62)	3.92 [0.98-19,96] $p=0.07$
PAI	38 (9.9%)	19 (7.5%)	19 (14.6%)	2.10 [1.06- 4.17] $p=0.03$
Traditional medicine	71 (18.5%)	46 (18.2%)	25 (19.2%)	1.07 [0.62- 1.83] $p=0.89$
Symptoms				
Fever	347 (90.6%)	231 (91.3%)	116 (89.2%)	0.79 [0.39-1.64] $p=0.58$
Muscle soreness/myalgia	249 (65.0%)	161 (63.6%)	88 (67.7%)	1.20 [0.77-1.88] $p=0.50$
Arthralgia	174 (45.4%)	110 (43.5%)	64 (49.2%)	1.26 [0.82-1.93] $p=0.33$
Headaches	261 (68.1%)	175 (69.2%)	86 (66.2%)	0.87 [0.56-1.37] $p=0.56$
Retro-orbital pain	98 (25.6%)	71 (28.1%)	27 (20.8%)	0.67 [0.40-1.11]
Diarrhea	129 (33.7%)	85 (33.6%)	44 (33.8%)	1.01 [0.64-1.58] $p=1.0$
Nausea/vomiting	209 (54.6%)	135 (53.4%)	74 (56.9%)	1.15 [0.75-1.77] $p=0.52$
Skin rash	130 (33.9%)	95 (37.5%)	35 (26.9%)	0.61 [0.38-0.97] $p=0.041$
Conjunctival hyperemia	41 (10.7%)	33 (13.0%)	8 (6.2%)	0.44 [0.18-0.95] $p=0.053$
Edema	18 (4.7%)	8 (3.2%)	10 (7.7%)	2.54 [0.96-6.90] $p=0.071$
Gingivorrhagia	58 (15.1%)	33 (13.0%)	25 (19.2%)	1.59 [0.89-2.80] $p=0.13$
Purpura	78 (20.4%)	47 (18.6%)	31 (23.8%)	1.37 [0.81-2.29] $p=0.23$
Epistaxis	58 (15.1%)	34 (13.4%)	24 (18.5%)	1.46 [0.81-2.58] $p=0.23$
Hematuria/blood in stools	19 (5.0%)	6 (2.4%)	13 (10%)	4.49 [1.71-13.30] $p<0.01$
Alert signs				
Abdominal pain	147 (38.4%)	88 (34.8%)	59 (45.4%)	1.56 [1.01-2.40] $p=0.046$
Persistent vomiting	42 (11.0%)	28 (11.1%)	14 (10.7%)	0.97 [0.48-1.90] $p=1.0$
Clinical liquid accumulation	28 (7.3%)	11 (4.3%)	17 (13.1%)	3.28 [1.50-7.50] $p<0.01$

Mucosal bleeding	170 (44.4%)	83 (32.8%)	87 (66.9%)	4.12 [2.64-6.51] <i>p</i> <0.01
Lethargy/anxiety	72 (18.8%)	46 (18.2%)	26 (20.0%)	1.13 [0.65-1.92] <i>p</i> =0.68
Hepatomegaly	17 (4.4%)	9 (3.6%)	8 (6.2%)	1.78 [0.64-4.83] <i>p</i> =0.30
Increase in Ht and platelet count drop	68 (17.8%)	37 (14.6%)	31 (23.8%)	1.83 [1.07-3.12] <i>p</i> =0.034
Biological parameters				
Normal platelet count	225 (58.7%)	175 (69.1%)	50 (38.4%)	Reference
Platelets < 30x10 ⁹ /L	134 (35.0%)	59 (23.3%)	75 (57.7%)	4.42 [2.79–7.08] <i>p</i> <0.01
GFR < 60 ml/min	42 (11.0%)	8 (3.1%)	34 (26.1%)	9.28 [4.22–22.90] <i>p</i> <0.01
Normal AST	217 (56.7%)	157 (62%)	60 (46.1%)	Reference
AST > 10N	110 (28.7%)	51 (20%)	59 (45.4%)	3.01 [1.87–4.89] <i>p</i> <0.01
Normal ALT	275 (71.8%)	198 (78.3%)	77 (59.2%)	Reference
ALT > 10N	51 (13.3%)	10 (3.9%)	41 (31.5%)	10.34 [5.10–22.94] <i>p</i> <0.01

^a*Kava: traditional beverage produced from poivrier roots, consumed throughout the cultures of Polynesia, Melanesia, and parts of Micronesia for its sedating and euphoriant effect.*

^b*Risk of bleeding refers to comorbidities with previous risk of hemorrhage (menorrhagia, endometriosis, adenomyosis, gastric ulcer, immunological thrombopenic purpura).*

PAI = Platelet Aggregation Inhibitor, NSAID = Non-Steroidal Anti-Inflammatory, GFR = Glomerular Filtration Rate, AST: Aspartate AminoTransferase, ALT: Alanine AminoTransferase.

Table 2. Clinical and biological parameters at hospital admission in the 383 hospitalized patients

Clinical parameters	Number (%)
Symptom	
Fever	347 (90.6%)
Muscle soreness/myalgia	249 (65.0%)
Arthralgia	174 (45.4%)
Headache	261 (68.1%)
Retro-orbital pain	98 (25.6%)
Diarrhea	129 (33.7%)
Nausea/vomiting	209 (54.6%)
Skin rash	130 (33.9%)
Conjunctival hyperemia	41 (10.7%)
Edema	18 (4.7%)
Gingivorrhagia	58 (15.1%)
Purpura	78 (20.4%)
Epistaxis	58 (15.1%)
Hematuria/blood in stools	19 (5.0%)
Shock syndrome	26 (6.8 %)
Major bleeding	47 (12.3%)
Alert signs	
Abdominal pain	147 (38.4%)
Persistent vomiting	42 (11.0%)
Clinical liquid accumulation	28 (7.3%)
Mucosal bleeding	170 (44.4%)
Lethargy/anxiety	72 (18.8%)
Hepatomegaly	17 (4.4%)
Increase in hematocrit + drop in platelets count	68 (17.8%)
Biological parameters	Median [min; max] (% of available results)
Platelets (10 ⁹ /L)	48 [3; 360](93.7)
Hemoglobin (g/dL)	14 [6; 22] (94.5)
Hematocrit (%)	41 [16; 61] (94)
Neutrophils (/mm ³)	1,895 [320; 19,020] (92)
Lymphocytes (/mm ³)	1,535 [140; 8,940] (90.8)
Albuminaemia (g/L)	36 [19; 46] (13.8)
Protidaemia (g/L)	58 [24; 91] (10.4)
Urea (mmol/L)	4 [0; 41](76)

Creatinin ($\mu\text{mol/L}$)	71 [18; 927] (78.3)
AST (IU/L)	184 [17; 10,336](85)
ALT (IU/L)	116 [9; 8,040] (85)
CPK	305 [3- 74,063] (28)
Lipase (IU/L)	53 [9; 2,707](33.4)
CRP (mg/L)	14 [0; 327] (56.6)

Table 3. Results of multivariate analysis concerning determinant factors of dengue severity used to build the predictive models for females and males.

	Crude odds ratio	Adjusted odds ratio (females)	Adjusted odds ratio (males)
Age class (years)			
≤10	0.77 [0.28 – 2.05]	2.52 [0.39 – 16.94]	0.77 [0.12 – 4.72]
]10-20]	1.26 [0.55 – 2.98]	3.22 [0.62 - 19.57]	0.88 [0.18 - 4.52]
]20-30]	2.22 [1.01 – 5.10]	7.79 [1.87 – 41.86]	0.26 [0.04 – 1.57]
]40-60]	2.04 [0.94 – 4.64]	5.74 [1.33 - 31.35]	1.21 [0.24 - 6.37]
>60	3.17 [1.42 – 7.44]	3.54 [0.58 – 24.36]	8.45 [1.59 – 53.3]
Hypertension	2.7 [1.6 – 4.7]	4.68 [1.24 - 19.75]	
Alcohol consumption	2.46 [0.62 - 10.56]		20.83 [1.93 - 807.49]
Mucosal bleeding	4.12 [2.64 - 6.51]	4.66 [2.08 – 11.14]	9.79 [3.75 - 28.72]
Clinical liquid accumulation	3.28 [1.50 – 7.50]	3.88 [0.87 - 18.19]	
Skin rash	0.61 [0.38 - 0.97]	0.41 [0.16 - 0.97]	
Platelets			
<30.10 ⁹ /L	4.42 [2.79 – 7.08]	2.83 [1.26 - 6.45]	5.84 [2.21 - 17.04]
ALT (IU/L)			
≥10N	10.34 [5.10 – 22.94]	14.31 [4.93 – 47.67]	243.09 [28.75 – 6130.86]

All parameters are risk factors for dengue severity albeit skin rash that appears as a protective factor to develop severe dengue in females.

Figure legends

Figure 1. Monthly dengue incidence rates in New Caledonia from 1971 to 2018.

Timeline of monthly dengue incidence rates per 10,000 inhabitants in New Caledonia from 1971 to 2018, showing an increasing frequency of outbreaks. For the first time in 2017, we observed a co-circulation of 3 serotypes (DENV-1, DENV-2, DENV-3).

Figure 2. Classification of the 383 hospitalized patients according to the presence of alert and severity signs (2017 dengue outbreak, New Caledonia).

Scheme of dengue cases distribution, showing the percentage of cases with and without alert signs and their evolution to non-severe and severe dengue, according to the WHO 2009 classification adapted for our study with minor modifications (thrombocytopenia $<10 \times 10^9/L$ associated to minor bleeding was used as an additional severity criterion).

Figure 3. Clinical signs of severity and comorbidities.

Percentage of cases exhibiting the indicated clinical signs of severity within the cohort (gray) and among severe cases (black).

Figure 4. Performance of predictive models for severe dengue according to the sex, New Caledonia 2017.

Receiving Operating Characteristic (ROC) curve for the best model for females (A) and the best model for males (B). Median AUC, Sensitivity, Specificity, Positive Predictive Value (PPV), Negative Predictive Value (NPV), Youden index and Yule Q coefficient are indicated for each model.

Supplementary Material

S1 Fig. STROBE flowchart describing patients enrolment in the study.

S2 Fig. Excel spreadsheet enabling the calculation of a bedside score predictive of severe dengue. In the operating tool, scores derived from the logistic regression models can be calculated using an Excel spreadsheet by inserting 1 if the characteristic is present. A score ≥ 0.36 for females and 0.34 for males indicates a high probability to develop severe dengue. The hospitalization decision is made according to the medical opinion. During hospitalization, patients are submitted to close surveillance, hyperhydration, symptomatic treatments and sometimes blood support and resuscitation measures.

S3 Fig. Examples of scoring to estimate the risk to develop severe dengue using data available at the moment of hospital admission decision. In the upper example, the score of the female patient is above 0.36, indicating a high risk to develop severe dengue. In the lower example, the score of the male patient is below 0.34, indicating a low probability to develop severe dengue.

S4 Fig. Contingency tables showing the performance of the models for the prediction of dengue severity on dengue 2018 outbreak in New Caledonia.

Absolute numbers of severe dengue observed in the dataset and predicted by the models are shown for the model for females (upper table) and the model for males (lower table).

Figure 1




Figure 2




Figure 3




Figure 4

